Representative Matters
代表事项
REFERENZMANDATE
General Corporate Counseling and Significant Transactions
- Kymera Therapeutics in connection with its $30 million Series A financing, $65 million Series B financing and its $102 million Series C financing, its strategic collaborations with Vertex Pharmaceuticals and Sanofi, its $200 million initial public offering, its $200 million follow-on public offering, and $150 million PIPE.
- Relay Therapeutics in connection with its $57 million Series A financing, its $63 million Series B financing and its $400 million Series C financing, its $460 million initial public offering, and multiple follow-on offerings of more than $300 million, and its $85 million acquisition of ZebiAI.
- EQRx in connection with its $200 million Series A financing and $500 million Series B Financing, its $5.35 billion business combination with CM Life Sciences III, including its $1.2 billion PIPE financing.
- Nimbus Therapeutics in connection with its multi-target strategic alliance with Celgene Corporation in immunology, the $1.2 billion sale of its ACC inhibitor program to Gilead Biosciences, its $60 million financing, $105 million financing and $125 million financing completed since 2020.
- Forma Therapeutics in connection with its $100 million Series D financing, its $319.3 million initial public offering, its $275.8 million follow-on public offering, its $200 million “at-the-market” offering, and its $1.1 billion sale to Novo Nordisk.
- ROME Therapeutics with its $50 million Series A financing and $77 million Series B financing
- Accent Therapeutics in its $63.5 million Series B financing
- Tango Therapeutics in connection with its $55 million Series A financing and its $60 million Series B financing, and its $1.0 billion definitive business combination with BCTG Acquisition Corp.
- Magenta Therapeutics in connection with its $48.5 million Series A financing and its $50 million Series B financing, and its $100 million initial public offering
- Intellia Therapeutics in connection with its foundational license agreement with Caribou Biosciences pursuant to which Intellia has the right to therapeutic applications of CRISPR/Cas9 technology, its collaboration and license agreements with Novartis and Regeneron, its $124.2 million initial public offering, and its $150 million follow-on public offering
- Obsidian Therapeutics in connection with its $49.5 million Series A financing and $115 million Series B financing, and its strategic collaboration with Celgene Corporation
- Disc Medicine in connection with its $50 million Series A financing and its $90 million Series B financing, and its reverse merger transaction with Gemini Therapeutics
- Ikena Oncology in connection with its $120 million Series B financing and its $143.8 million initial public offering
- Orionis Biosciences in its research collaboration and financing transaction with Novartis
- Sionna Therapeutics in its $111 million Series B financing
- HotSpot Therapeutics, Inc. in its $100 million Series C financing
- Oak Hill Bio in its formation, financing and acquisition of three programs from Takeda
Issuer-Side Capital Markets Transactions
- Rocket Pharmaceuticals in its $299 million follow-on financing
- Candel Therapeutics in its $72 million initial public offering
- Praxis Precision Medicines in its $104.9 million underwritten public offering
- TCR2 Therapeutics in its $75 million underwritten public offering
- Bluebird bio in its $116.1 million initial public offering
- Other clinical stage and commercial stage issuers in more than $5 billion in equity and debt offerings
Mergers and Acquisitions
- Thrive Earlier Detection Corp. in connection with its $2.15 billion sale to Exact Sciences Corporation
- Rodin Therapeutics in its $950 million sale to Alkermes
- Padlock Therapeutics in its $600 million sale to Bristol-Meyers Squibb
- Ocata Therapeutics in its sale to Astellas
- Albany Molecular Research Inc. in its sale to The Carlyle Group and GTCR
- Outcome Sciences in its sale to Quintiles Transnational (NASDAQ: Q)
- ZOLL Medical in its acquisition of Kyma Medical Systems and other business development transactions
Mr. Collins also represents leading life science venture capital and investment firms, including Atlas Venture, Third Rock Ventures, Curie Bio, Newpath Partners, Bain Capital Life Sciences, Lightstone Ventures, Vida Ventures and others, in connection with their portfolio investments and related matters.
Professional Activities
Mr. Collins is a member of the Boston and American Bar Associations.
Professional Experience
Prior to joining Goodwin, Mr. Collins was an Economic Justice Fellow at the Lawyers’ Committee for Civil Rights, where he coordinated with community groups and local attorneys to bring pro bono business legal services to low-income and minority entrepreneurs in Eastern Massachusetts. Mr. Collins continues to be an active participant in Goodwin’s Neighborhood Business Initiative, which has for more than 15 years served the legal needs of low-income and minority entrepreneurs in the Greater Boston area.
